[Use of an anti-arrhythmia drug mexicord in the treatment of ventricular extrasystole].
The antiarrhythmic agent mexicord (Polfa, Poland) versus ethmozine underwent a clinical trial. Meticord was found to have a marked antiarrhythmic effect and be useful in the long-term management of patients with ventricular tachyarrhythmias.
Urumbaev
R K
RK
Suprunova
I P
IP
Imanakunova
D Sh
DSh
Rakhimova
G R
GR
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage*; D008875:Middle Aged; D016293:Moricizine / Q000008:administration & dosage*; D011044:Poland; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D016293:Moricizine